Cefoperazone/sulbactam in Treatment of Biliary Tract Infections:A Prospective Multicenter Clinical Trial
- VernacularTitle:头孢哌酮/舒巴坦治疗胆道感染的前瞻性、多中心临床研究
- Author:
Zhanliang LI
;
Tonglin ZHANG
;
Zhi XU
;
Lei YANG
;
Jiafeng LIU
;
Lijian LIANG
;
Jiaming LAI
;
Ping ZHANG
;
Chenghong PENG
;
Hao CHEN
;
Zhiwei QUAN
;
Shenglai ZHANG
;
Tingbo LIANG
;
Weilin WANG
;
Feizhao JIANG
;
Zhiwei ZHANG
;
Bixiang ZHANG
;
Naiqiang CUI
;
Qiang FU
;
Qiang LI
;
Min XIE
- Publication Type:Journal Article
- Keywords: Biliary tract Infection; Cefoperazone/sulbactam; Therapy
- From: Chinese Journal of Nosocomiology 1994;0(04):-
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE To evaluate the safety and clinical efficacy of cefoperazone/sulbactam in the treatment of biliary tract infections.METHODS In this prospective multicenter study,159 hospitalized patients with biliary tract infections received cefoperazone/sulbactam,and the clinical and bacteriological efficacy as well as the side effects were evaluated.RESULTS The clinical effective rate of cefoperazone/sulbactam in the treatment of biliary tract infections was 86.78%.After treatment,the body temperature reduced to normal rapidly,the average time of defervescence was 3.09?1.81 days.Pathogen eradication rate was 85.71%.No adverse reactions were reported during the study period.CONCLUSIONS Cefoperazone/sulbactam can be used as one of antibiotics of choice in the initial empirical therapy for biliary tract infections.